<?xml version="1.0" encoding="UTF-8"?>
<p>Cannabidiol (CBD) is generally made from the 
 <italic>Cannabis sativa</italic> L. plant [
 <xref rid="B17-animals-11-00892" ref-type="bibr">17</xref>,
 <xref rid="B27-animals-11-00892" ref-type="bibr">27</xref>]. The plant contains hundreds of different active compounds and of these, more than 100 are cannabinoids which, depending on the compound, have either psychoactive or non-psychoactive effects. CBD is a non-psychoactive lipid cannabinoid [
 <xref rid="B19-animals-11-00892" ref-type="bibr">19</xref>]. CBD has been used in human medicine to mitigate anxiety [
 <xref rid="B28-animals-11-00892" ref-type="bibr">28</xref>], improve appetite [
 <xref rid="B29-animals-11-00892" ref-type="bibr">29</xref>], relieve nausea [
 <xref rid="B30-animals-11-00892" ref-type="bibr">30</xref>], control seizures of certain types [
 <xref rid="B31-animals-11-00892" ref-type="bibr">31</xref>], and assist in the management of sleep disorders [
 <xref rid="B32-animals-11-00892" ref-type="bibr">32</xref>]. Assorted CBD products are available throughout Europe for human use both online and through dispensaries [
 <xref rid="B33-animals-11-00892" ref-type="bibr">33</xref>]. A similar scenario exists in the US where CBD products are also widely available and often marketed for therapeutic purposes. To legally market such products, claims of safety and efficacy must be substantiated through the federal government approval process. If such CBD products are not granted such approval, they cannot be legally marketed and, with one exception, all products in the US that have such a therapeutic claim have not been approved [
 <xref rid="B7-animals-11-00892" ref-type="bibr">7</xref>] (See also 
 <xref ref-type="sec" rid="sec5-animals-11-00892">Section 5</xref> “The Industry of Cannabis in North America” and 
 <xref ref-type="sec" rid="sec6-animals-11-00892">Section 6</xref> “Regulatory Framework in the EU and North America”).
</p>
